Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Operations (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Cash from Operations for 5 consecutive years, with 21745000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 18.16% year-over-year to 21745000.0, compared with a TTM value of 82503000.0 through Dec 2025, down 2.18%, and an annual FY2025 reading of 82503000.0, down 2.18% over the prior year.
  • Cash from Operations was 21745000.0 for Q4 2025 at Aligos Therapeutics, up from 24345000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 13616000.0 in Q2 2023 and bottomed at 37480000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 21864700.0, with a median of 21327000.0 recorded in 2025.
  • The sharpest move saw Cash from Operations soared 55.22% in 2022, then tumbled 43.16% in 2024.
  • Year by year, Cash from Operations stood at 37480000.0 in 2021, then skyrocketed by 55.22% to 16783000.0 in 2022, then plummeted by 35.01% to 22658000.0 in 2023, then grew by 18.78% to 18403000.0 in 2024, then fell by 18.16% to 21745000.0 in 2025.
  • Business Quant data shows Cash from Operations for ALGS at 21745000.0 in Q4 2025, 24345000.0 in Q3 2025, and 15504000.0 in Q2 2025.